Clinical trials: Hyperuricemia, Gout
Hyperuricemia or Gout
Clinical Efficacy Trial of Burdock Root Extract in Patients With Asymptomatic Hyperuricaemia
Multicentre, double-blind, randomized, placebo-controlled trial of the clinical efficacy of burdock root extract in patients with asymptomatic hyperuricemia, with the primary objective to assess the efficacy of the use of burdock…
- Trial name
- NCT07002762
- Testing
- Burdock ( Arctium lappa L.) root extract in a form of a nutritional additive
- Where
- Ukraine
- Volunteers
- 100 people
- Sponsor
- OMNIFARMA LLC
Gout, Hyperuricemia
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.
- Trial name
- NCT02252835
- Testing
- Arhalofenate, Febuxostat, Colchicine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Hyperuricemia
Study of FYU-981 in Hyperuricemia With or Without Gout
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered…
- Trial name
- NCT02344862
- Testing
- FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Fuji Yakuhin Co., Ltd.
Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
- Trial name
- NCT07089888
- Testing
- Allopurinol, Dotinurad
- Where
- 96 sites in United States
- Volunteers
- 250 people
- Sponsor
- Crystalys Therapeutics
Moderate to Severe Gout, Hyperuricemia
Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe…
- Trial name
- NCT01109121
- Testing
- Combination 400, Allopurinol, Combination 600
- Where
- 24 sites in United States
- Volunteers
- 112 people
- Sponsor
- Nuon Therapeutics, Inc.
Gout Attack
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
The primary goal of the study was to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.
- Trial name
- NCT04067492
- Testing
- RPH - 104, Voltaren®
- Where
- 11 sites in Russia
- Volunteers
- 47 people
- Sponsor
- R-Pharm
Gout, Hyperuricemia
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a…
- Trial name
- NCT03934099
- Testing
- LC350189 formulated capsule
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- LG Chem
Hyperuricemia
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
The purpose of this study is to determine whether RDEA806 is effective in the treatment of hyperuricemia in gout patients.
- Trial name
- NCT00741442
- Testing
- RDEA806
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Ardea Biosciences, Inc.
Gout, Hyperuricemia
Mass Balance Study of [14C]LC350189 in Healthy Volunteers
This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of [14C] radiolabeled LC350189 after oral administration.
- Trial name
- NCT04070846
- Testing
- [14C] LC350189
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- LG Chem
Gout, Hyperuricemia
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy…
- Trial name
- NCT03927677
- Testing
- Xanthine Oxidase Inhibitor
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Chem
Gout
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels
This is a Phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels.
- Trial name
- NCT05745727
- Testing
- PRX-115
- Where
- 2 sites in New Zealand
- Volunteers
- 64 people
- Sponsor
- Protalix
Gout, Hyperuricemia
Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
This is a Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients with Hyperuricemia.
- Trial name
- NCT04040816
- Testing
- SAP-001
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Shanton Pharma Co., Ltd.
Gout, Arthritis, Gouty
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Trial name
- NCT06846515
- Testing
- AR882 50 mg, AR882 75 mg
- Where
- 83 sites in United States
- Volunteers
- 866 people
- Sponsor
- Arthrosi Therapeutics
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hyperuricemia, Gout
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy…
- Conditions
- Hyperuricemia, Gout, Qt Interval, Variation in
- Trial name
- NCT04966325
- Testing
- LC350189 200mg, Moxifloxacin 400mg, LC350189 600mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- LG Chem
Gout, Hyperuricemia
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
This is a safety, tolerability, pharmacokinetics, and preliminary pharmacological study of multiple administration, dose escalation, randomized double-blind, placebo-controlled.The main purpose of this experiment is to evaluate…
- Trial name
- NCT06629376
- Testing
- Pegylated Recombinant Candida Utilis Uricase for Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gout
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.
- Trial name
- NCT02187029
- Testing
- PF-06743649
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Gout, Hyperuricemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
- Trial name
- NCT03906006
- Testing
- ABP-671
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd
Gout Chronic, Hyperuricemia
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple…
- Trial name
- NCT02959918
- Testing
- SEL-212, SEL-037, SVP-rapamycin (SEL-110)
- Where
- 13 sites in United States
- Volunteers
- 152 people
- Sponsor
- Selecta Biosciences, Inc.
Gout, Hyperuricemia
Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
This is a Phase I, Multicenter, Randomized, Double-blind, Placebo controlled, Dose-escalation study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAP-001 in Gout Patients with…
- Trial name
- NCT03857165
- Testing
- SAP-001
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shanton Pharma Co., Ltd.